Share Buy-back and Total Voting Rights

RNS Number : 8875O
Access Intelligence PLC
04 June 2020
 

4 June 2020

Access Intelligence plc

("Access Intelligence" or the "Company")

Share Buy-back and Total Voting Rights

Access Intelligence (AIM: ACC), the technology innovator delivering Software-as-a-Service ("SaaS") solutions for the PR, communications and marketing industries, is pleased to confirm that it completed the share buyback from Cello Health plc ("Cello"). It was announced on 6 February 2020, following completion of the Pulsar accounting review, that Cello had agreed to sell back 4,076,238 ordinary shares of 5 pence each in the Company ("Ordinary Shares") to the Company for £1 (the "Buy-back"). The Company required the requisite approvals to acquire these shares and this approval was sought and gained at the Company's annual general meeting held on 20 May 2020. Accordingly, the Company has now bought these shares back and the shares have been cancelled.

 

Following the Buy-back, the Company has 75,146,515 Ordinary Shares in issue. The Company holds 2,966,666 Ordinary Shares in treasury and therefore, the total number of Ordinary Shares in the Company with voting rights will be 72,179,849. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

 

Enquiries:

Access Intelligence plc

020 3426 4024

Joanna Arnold, CEO


Mark Fautley, CFO

 



finnCap Limited  (Nominated Adviser and Broker)

020 7220 0500

Corporate Finance:

Marc Milmo/Kate Bannatyne/Matthew Radley

 

Corporate Broking:

Alice Lane/Sunila de Silva




 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TVRGZGGVNFDGGZM
UK 100